Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCSK9 Inhibitors and Plaque Morphology in Early-Onset CAD
NCT06520904Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Xinjiang Medical University
- Start
- Jul 2024
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in coronary artery disease (CAD) (2 arms), sponsored by First Affiliated Hospital of Xinjiang Medical University. Primary endpoints: Minimum Fibrous Cap Thickness at 1 year, Maximum Lipid Arc at 1 year and 4 more. Started Jul 2024; status: recruiting.
02
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT06520904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06520904.